KRMD

Repro Med Systems Inc
NASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$210.83M
P/E Ratio
EPS
$-0.05
Beta
0.41
52W High
$6.61
52W Low
$2.91
50-Day MA
$4.09
200-Day MA
$4.58
Dividend Yield
Profit Margin
-5.27%
Forward P/E
188.68
PEG Ratio

About Repro Med Systems Inc

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$43.26M
Gross Profit (TTM)$26.79M
EBITDA$-1.92M
Operating Margin-7.35%
Return on Equity-13.70%
Return on Assets-5.81%
Revenue/Share (TTM)$0.94
Book Value$0.37
Price-to-Book12.19
Price-to-Sales (TTM)4.87
EV/Revenue4.643
EV/EBITDA-17.15
Quarterly Earnings Growth (YoY)-66.00%
Quarterly Revenue Growth (YoY)22.10%
Shares Outstanding$45.93M
Float$34.15M
% Insiders8.01%
% Institutions57.08%

Historical Volatility

HV 10-Day
48.15%
HV 20-Day
44.05%
HV 30-Day
45.30%
HV 60-Day
48.78%
HV Rank
33.7%

Volatility is currently expanding

Analyst Ratings

Consensus ($6.80 target)
4
Buy
1
Hold

Latest News

KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company presented its latest research at the Oncology Nursing Society (ONS) Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The ONS abstract evaluated nur.

Business Wire5/18/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026